5 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 32 points (0.2%) at 14,286 as of Wednesday, March 6, 2013, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,509 issues advancing vs. 1,334 declining with 158 unchanged.

The Health Care sector currently sits up 0.3% versus the S&P 500, which is up 0.1%. Top gainers within the sector include Vertex Pharmaceuticals ( VRTX), up 2.2%, Aetna ( AET), up 1.9%, Celgene Corporation ( CELG), up 1.6%, Teva Pharmaceutical Industries ( TEVA), up 1.4% and Regeneron Pharmaceuticals ( REGN), up 0.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:

5. Pharmacyclics Incorporated ( PCYC) is one of the companies pushing the Health Care sector higher today. As of noon trading, Pharmacyclics Incorporated is up $2.24 (2.4%) to $95.00 on average volume Thus far, 421,751 shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 632,100 shares. The stock has ranged in price between $92.81-$95.85 after having opened the day at $93.00 as compared to the previous trading day's close of $92.76.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $6.4 billion and is part of the drugs industry. The company has a P/E ratio of 73.2, above the S&P 500 P/E ratio of 17.7. Shares are up 60.5% year to date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Pharmacyclics Incorporated as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pharmacyclics Incorporated Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015